Mounjaro dosage
The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. The maximum dosage of MOUNJARO is: 15 mg injected subcutaneously once weekly in adults. 10 mg injected subcutaneously once weekly in pediatric patients.
Word for word from the FDA label on DailyMed (Eli Lilly and Company), revised , version 40. Read every day: a new FDA version updates this page by itself.
Mounjaro dosage chart
The soonest the label's schedule allows. A clinician can go slower.
| When | Dose |
|---|---|
| Weeks 1 to 4 | 2.5 mg |
| Week 5 or later | 5 mgif more control is needed |
| Week 9 or later | 7.5 mgif more control is needed |
| Week 13 or later | 10 mgif more control is needed |
| Week 17 or later | 12.5 mgif more control is needed |
| Week 21 or later | 15 mgif more control is needed |
Mounjaro dosing and administration
Recommended Dosage
Follow the starting dosage recommendation and dosage escalation schedule below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)].
Recommended Starting Dosage and Escalation
- The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly [see Dosage and Administration (2.2)] .
- If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.
- The maximum dosage of MOUNJARO is: 15 mg injected subcutaneously once weekly in adults. 10 mg injected subcutaneously once weekly in pediatric patients.
Recommendations Regarding Missed Doses
- If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
- The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).
Important Administration Instructions
- Inform patients and their caregiver(s) which MOUNJARO presentation (e.g., vial, pre-filled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.
- Prior to initiation, train patients and their caregiver(s) on proper injection technique for the prescribed MOUNJARO presentation [see Instructions for Use] . After training, a patient may self-inject MOUNJARO if the healthcare provider determines that it can be properly administered, except for the following: MOUNJARO KwikPen is not recommended for self-administration by pediatric patients. MOUNJARO KwikPen is not recommended for self-administration by those who are visually impaired.
- Instruct patients using MOUNJARO vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.
- Administer MOUNJARO once weekly, any time of day, with or without meals.
- Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm.
- Rotate injection sites with each dose.
- Inspect MOUNJARO visually before use. It should appear clear and colorless to slightly yellow. Do not use MOUNJARO if particulate matter or discoloration is seen.
- When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.
Source: Mounjaro prescribing information (FDA label on DailyMed), revised 2026-08-27
Mounjaro strengths and forms
Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses:
| Single-dose Pen or Vial |
|---|
| 2.5 mg/0.5 mL |
| 5 mg/0.5 mL |
| 7.5 mg/0.5 mL |
| 10 mg/0.5 mL |
| 12.5 mg/0.5 mL |
| 15 mg/0.5 mL |
| Multi-dose Vial (4 doses per vial) | Multi-dose Vial (4 doses per vial) | Multi-dose Vial (4 doses per vial) |
|---|---|---|
| Dose per Injection | Total Strength per Total Volume | Strength per mL |
| 2.5 mg/0.6 mL | 10 mg/2.4 mL | 4.17 mg/mL |
| 5 mg/0.6 mL | 20 mg/2.4 mL | 8.33 mg/mL |
| 7.5 mg/0.6 mL | 30 mg/2.4 mL | 12.5 mg/mL |
| 10 mg/0.6 mL | 40 mg/2.4 mL | 16.7 mg/mL |
| 12.5 mg/0.6 mL | 50 mg/2.4 mL | 20.8 mg/mL |
| 15 mg/0.6 mL | 60 mg/2.4 mL | 25 mg/mL |
| Single-Patient-Use KwikPen (4 doses per KwikPen) | Single-Patient-Use KwikPen (4 doses per KwikPen) | Single-Patient-Use KwikPen (4 doses per KwikPen) |
|---|---|---|
| Dose per Injection | Total Strength per Total Volume | Strength per mL |
| 2.5 mg | 10 mg/2.4 mL | 4.17 mg/mL |
| 5 mg | 20 mg/2.4 mL | 8.33 mg/mL |
| 7.5 mg | 30 mg/2.4 mL | 12.5 mg/mL |
| 10 mg | 40 mg/2.4 mL | 16.7 mg/mL |
| 12.5 mg | 50 mg/2.4 mL | 20.8 mg/mL |
| 15 mg | 60 mg/2.4 mL | 25 mg/mL |
Source: Mounjaro prescribing information (FDA label on DailyMed), revised 2026-08-27
How to store Mounjaro
How Supplied
MOUNJARO is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens, 1 single-dose vial, 1 multi-dose vial, or 1 Single-Patient-Use KwikPen as follows:
| Single-Dose Vial and Prefilled Pen | Single-Dose Vial and Prefilled Pen | Single-Dose Vial and Prefilled Pen |
|---|---|---|
| Strength | 4-pack Single-dose Pen NDC | 1-pack Single-dose Vial NDC |
| 2.5 mg/0.5 mL | 0002-1506-80 | 0002-1152-01 |
| 5 mg/0.5 mL | 0002-1495-80 | 0002-1243-01 |
| 7.5 mg/0.5 mL | 0002-1484-80 | 0002-2214-01 |
| 10 mg/0.5 mL | 0002-1471-80 | 0002-2340-01 |
| 12.5 mg/0.5 mL | 0002-1460-80 | 0002-2423-01 |
| 15 mg/0.5 mL | 0002-1457-80 | 0002-3002-01 |
| Multi-Dose Vial | Multi-Dose Vial | Multi-Dose Vial |
|---|---|---|
| Doses per Vial | Strength | 1-pack Multi-dose Vial NDC |
| 4 doses of 2.5 mg/0.6 mL | 10 mg/2.4 mL (4.17 mg/mL) | 0002-4052-11 |
| 4 doses of 5 mg/0.6 mL | 20 mg/2.4 mL (8.33 mg/mL) | 0002-4103-11 |
| 4 doses of 7.5 mg/0.6 mL | 30 mg/2.4 mL (12.5 mg/mL) | 0002-4210-11 |
| 4 doses of 10 mg/0.6 mL | 40 mg/2.4 mL (16.7 mg/mL) | 0002-4304-11 |
| 4 doses of 12.5 mg/0.6 mL | 50 mg/2.4 mL (20.8 mg/mL) | 0002-4523-11 |
| 4 doses of 15 mg/0.6 mL | 60 mg/2.4 mL (25 mg/mL) | 0002-4612-11 |
| Single-Patient-Use KwikPen (with four weekly doses) | Single-Patient-Use KwikPen (with four weekly doses) | Single-Patient-Use KwikPen (with four weekly doses) |
|---|---|---|
| Doses per KwikPen | Strength | 1-pack Single-Patient-Use KwikPen NDC |
| 4 doses of 2.5 mg | 10 mg/2.4 mL (4.17 mg/mL) | 0002-3466-11 |
| 4 doses of 5 mg | 20 mg/2.4 mL (8.33 mg/mL) | 0002-3455-11 |
| 4 doses of 7.5 mg | 30 mg/2.4 mL (12.5 mg/mL) | 0002-3444-11 |
| 4 doses of 10 mg | 40 mg/2.4 mL (16.7 mg/mL) | 0002-3433-11 |
| 4 doses of 12.5 mg | 50 mg/2.4 mL (20.8 mg/mL) | 0002-3422-11 |
| 4 doses of 15 mg | 60 mg/2.4 mL (25 mg/mL) | 0002-3411-11 |
Storage and Handling
- Do not freeze MOUNJARO. Do not use MOUNJARO if frozen.
- Protect MOUNJARO from heat and light.
- Store MOUNJARO in the original carton to protect from light.
MOUNJARO Single-dose Pen and Single-dose Vial
- Store MOUNJARO single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F).
- If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days.
- Discard the single-dose pen or single-dose vial after a total of 21 days at room temperature.
MOUNJARO Multi-dose Vial or Single-Patient-Use KwikPen
Unopened vial or single-patient-use KwikPen:
- Store unopened multi-dose vial or single-patient-use KwikPen in the refrigerator at 2°C to 8°C (36°F to 46°F). The unopened multi-dose vial or single-patient-use KwikPen can be used until the expiration date on the label if kept in the refrigerator.
- If stored at room temperature [up to 30°C (86°F)], throw away unopened multi-dose vial or single-patient-use KwikPen after 30 days.
After vial or single-patient-use KwikPen has been opened:
- Store opened (in-use) multi-dose vial or single-patient-use KwikPen in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].
- Throw away opened multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.
Source: Mounjaro prescribing information (FDA label on DailyMed), revised 2026-08-27
Mounjaro dosing: common questions
What should you expect in the first week of Mounjaro?
From its FDA label: The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Your clinician may adjust this.
Can you skip a week of Mounjaro?
Its FDA label covers a missed dose, not a planned break, so ask your prescriber before skipping one on purpose. On a missed dose it says: If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose.
What is the starting dose of Mounjaro?
The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly.
What is the maximum or maintenance dose of Mounjaro?
The maximum dosage of MOUNJARO is: 15 mg injected subcutaneously once weekly in adults. 10 mg injected subcutaneously once weekly in pediatric patients.
What if you miss a dose of Mounjaro?
If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose.
How long can Mounjaro stay out of the fridge?
If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days.
Where do you inject Mounjaro?
Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm.
When should you take Mounjaro?
Administer MOUNJARO once weekly, any time of day, with or without meals.
How do you use Mounjaro?
From its FDA-approved Medication Guide: Read the Instructions for Use that comes with MOUNJARO. Use MOUNJARO exactly as your healthcare provider tells you to. Your healthcare provider should show you how to prepare and inject your dose of MOUNJARO before injecting for the first time. A caregiver may give you MOUNJARO injections or you may self-inject if a healthcare provider determines that it is appropriate. Children should not inject themselves with MOUNJARO KwikPen. An adult caregiver should give a child his or her injections with MOUNJARO KwikPen. Self-injection is not recommended for people who are visually impaired. If using MOUNJARO vials, always use a new syringe and needle for each injection. Inject MOUNJARO under the skin (subcutaneously) of your stomach (abdomen), thigh, or another person should inject in the back of the upper arm. Do not inject MOUNJARO into a muscle (intramuscularly) or vein (intravenously). Use MOUNJARO 1 time each week, at any time of the day. You may change the day of the week you use MOUNJARO as long as the time between the 2 doses is at least 3 days (72 hours).
Dosing is decided by your clinician. This is the label's text for reference, not instructions for you.